Sandoz is a global leader in generic pharmaceuticals and biosimilars and a division of the Novartis Group. Sandoz contributes to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. That is our purpose.
Our business ambition is to be the world’s leading and most valued generics company.
Our global portfolio comprises approximately 1 000 molecules, covering a wide range of therapeutic areas, which accounted for 2020 sales of USD 9.6 billion. Our broad offering translates into substantial and ongoing savings for patients and payors, which help to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines.
Our products reach approximately 500 million patients every year. Our broad portfolio is spearheaded by our global leadership positions in both biosimilars, the “cutting edge” of innovative off-patent medicines, and generic antibiotics, the backbone of global healthcare systems. We also run a variety of targeted corporate responsibility programs. Sandoz Canada is headquartered in Boucherville, Québec, Canada.
Sandoz from a Canadian standpoint
A true leader in its field, Sandoz Canada markets and distributes a wide range of generics, biosimilars and specialty products. Sandoz Canada covers all major therapeutic areas with its broad portfolio of off-patent medicines and works closely with commercial and scientific partners to maximize its collective contribution to society.
Our ambition is to position Sandoz Canada as THE leader in Biosimilars & Generics powered by our people, portfolio and pipeline to serve as a trusted partner to pharmacies, hospitals, physicians and payers.